Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme-Reference-Cited by-同舟云学术

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme

Published:2022-02-17 Issue:4 Volume:26 Page:352-362
ISSN:1365-1501
Container-title:International Journal of Psychiatry in Clinical Practice
language:en
Short-container-title:International Journal of Psychiatry in Clinical Practice

Author:

Samalin Ludovic¹,Rothärmel Maud²,Mekaoui Lila³,Gaudré-Wattinne Emeline⁴,Codet Marie-Alix⁴,Bouju Sophie⁴,Sauvaget Anne⁵

Affiliation:

1. Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France

2. University Department of Psychiatry, Therapeutic Centre of Excellence, Institute of Psychiatry – Rouvray Hospital Centre, Sotteville-lès-Rouen, France

3. Mental and Brain Illness Clinic, Sainte-Anne Hospital, GHU Paris – Psychiatry and Neurosciences, Paris, France

4. Medical Affairs, Janssen-Cilag, Issy-les-Moulineaux, France

5. Nantes Université, CHU Nantes, Movement, Interactions, Performance (MIP), EA 4334, Nantes, France

Funder

Janssen-Cilag

Publisher

Informa UK Limited

Subject

Psychiatry and Mental health

Link

https://www.tandfonline.com/doi/pdf/10.1080/13651501.2022.2030757

Reference49 articles.

1. American Psychological Association. 2019. Clinical practice guideline for the treatment of depression across three age cohorts. [accessed 2021 March 10]. https://www.apa.org/depression-guideline/guideline.pdf

2. Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental

3. Treatment resistant depression incidence and prevalence using the French nationwide claims database

4. Acceptability, attitudes and knowledge towards Transcranial Magnetic Stimulation (TMS) among psychiatrists in France

5. Prise en charge des troubles dépressifs résistants : recommandations françaises formalisées par des experts de l’AFPBN et de la fondation FondaMental

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data;Journal of Affective Disorders;2024-03

2. Esketamine-induced post-traumatic stress disorder flashbacks during treatment-resistant depression indication: is it just a side effect?;2024-01-10

3. Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada;Frontiers in Psychiatry;2024-01-08

4. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review;Pharmaceutics;2023-12-13

5. Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries;Middle East Current Psychiatry;2023-12-07